author-photo

Louis Denis

VU University Amsterdam

181

Papers

10980

Citations

Citation Trend

Filter By

Papers (125) Sort By

Journal Conference Others

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B05: ASN007, an oral ERK1/2 inhibitor, shows strong antitumor activity across a panel of KRAS subtype mutant cancer models

2020
Show All
- Source
- Cite
- Save
Citations (0)
The relation between baseline PSA, cancer detection and PC death, long-term data from ERSPC

2019 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (0)
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

2019 European Urology
Show All
- Source
- Cite
- Save
Citations (147)
Abstract PR09: Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT019: ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
371PDA Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)